31 results about "Tumor penetration" patented technology

The invention relates to a preparation method and application of a shrinking particle size type tumor penetrating nano system sensitive to FAP-Alpha (fibroblast activation protein alpha) enzyme and reducing environment, and effectively solves the problem that a traditional drug delivery system has poor targeting performance, high toxic and side effects, single functionality, poor penetrating performance and difficulty in overcoming tumor microenvironment bio-barrier. According to the technical scheme to solve the problem, doxorubicin is connected with polyamidoamine through disulfide bonds as linker arms to form reduction-sensitive nanoparticles, the nanoparticles are connected with polypeptides linker arms sensitive to FAP-Alphaj to form the shrinking particle size type tumor penetrating nano system sensitive to FAP-Alpha enzyme and reducing environment; the shrinking particle size type tumor penetrating nano system sensitive to FAP-Alpha enzyme and reducing environment has the advantages of good biocompatibility, sensitiveness to enzymes and reducing environments, and capability to effectively overcome tumor microenvironment bio-barrier, and belongs to innovation on drug preparations for tumor therapy.

The present disclosure relates to RNA aptamers and uses thereof, in particular, aptamers which specifically bind to CD133 and which demonstrate superior tumor penetration.

The invention relates to the preparation and application of a sodium alginate-based variable particle size gating antitumor drug delivery system, which can effectively solve the problem of antitumor drug preparation; Peptide ligands were grafted on the sodium acid skeleton, mixed evenly with doxorubicin under ultrasonic conditions, and FeCl was added dropwise 3 A cross-linking agent, which covalently cross-links with -COOH on the molecular skeleton of sodium alginate to form a nano hydrogel, and at the same time packs doxorubicin in the space grid structure of the nano gel, namely; the preparation method of the present invention Simple, energy-saving and environmentally friendly, the prepared anti-tumor drug delivery system has the ability of tumor-triggered phase inversion, which can realize the release of drugs in response to the tumor microenvironment; realize the particle size transformation through the stimulation of the tumor microenvironment, and realize the deep penetration of the tumor; activate endogenous H 2 o 2 →•OH conversion, realize O-free 2 Participating in tumor chemokinetics-chemotherapy combination therapy, providing new ideas for improving the efficiency of chemotherapy drugs for tumor treatment.

The invention discloses a nucleic acid-loaded nanomaterial that increases tumor permeability in response to VEGF, comprising a drug-loaded nanoparticle core and a nucleic acid shell, and the nucleic acid shell includes DNA 1 、DNA 2 、DNA 3 and DNA 4 , DNA 3 Contains V7T1 nucleic acid aptamer that specifically recognizes VEGF protein. due to DNA 3 Contains VEGF nucleic acid aptamer, which can specifically recognize VEGF protein overexpressed in the tumor microenvironment, making DNA 3 and DNA 4 Shed from nucleic acid-drug-loaded nanoparticles, DNA 2 / DNA 1 The modified albumin drug-loaded nanoparticle has a small particle size and good tumor permeability; and the entire nucleic acid-drug-loaded nanomaterial is mainly composed of nucleic acid and protein, and has good biocompatibility. The invention also discloses the preparation method and application of the nucleic acid-drug-loaded nanometer material, which is simple in operation and low in cost.

The invention discloses a C-terminally modified tumor-penetrating peptide RGERPPR ferritin nanoparticle, its preparation method and application. The C-terminal modification of the ferritin nanoparticles of the tumor-penetrating peptide RGERPPR connects the tumor-penetrating peptide RGERPPR to the C-terminus of the ferritin through a linker sequence, and the tumor-penetrating peptide RGERPPR is exposed to the outside of the ferritin. The ferritin nanoparticles of the C-terminal modified tumor penetrating peptide RGERPPR of the present invention have strong targeting ability and cell penetrating power, and can have a strong combination with tumor cells, and the prepared antitumor drug has a strong Cytotoxicity provides a very good carrier model for subsequent drug-targeted tumor cell therapy and has a good application prospect.